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Abstract
The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration
with the United States Food and Drug Administration (FDA) a programmatic look at innovative
avenues for the identification of relevant parameters to assist clinical and basic scientists who study
the natural course of host/tumor interactions or their response to immune manipulation. The task
force has two primary goals: 1) identify best practices of standardized and validated immune
monitoring procedures and assays to promote inter-trial comparisons and 2) develop strategies for
the identification of novel biomarkers that may enhance our understating of principles governing
human cancer immune biology and, consequently, implement their clinical application. Two
working groups were created that will report the developed best practices at an NCI/FDA/iSBTc
sponsored workshop tied to the annual meeting of the iSBTc to be held in Washington DC in the
Fall of 2009. This foreword provides an overview of the task force and invites feedback from
readers that might be incorporated in the discussions and in the final document.
Background
Assumptions about correlation between immunological
end-points and clinical outcomes of immunotherapy or
anti-cancer vaccine therapy are not supported by current
monitoring strategies; standard immunological assays
may inform about immunological outcomes but cannot
yet predict the efficacy of treatment [1].
The failure of past clinical investigations to identify meas-
urable, reliable biomarkers predictive of treatment effi-
cacy may be explained two ways:
A. The current understanding of the immune biology of
tumor/host interactions and the immunological require-
ments for the induction of immune-mediated, tissue-spe-
cific destruction is insufficient. Thus, novel hypothesis-
generating strategies should be considered.
B. The power of immunotherapy clinical studies is often not
sufficient to provide robust statistical information because of
their small size and because the immune assays are not suffi-
ciently standardized or broad to allow inter-trial, inter-insti-
tutional comparisons to enhance statistical power.
To address the first point, a working group (Novel Assays
for Immunotherapy Clinical Trials) has been organized
under the leadership of Peter Lee and Francesco Marincola
aimed at the identification of experimental, bioinformat-
ics and clinical strategies to increase the yield of informa-
tion relevant to the mechanism of immune-mediated,
tissue-specific rejection to develop clinically useful mark-
ers and assays.
To address the second point, another working group
(Biomarker Validation and Application) has been organized
under the leadership of Lisa Butterfield, Nora Disis and
Karolina Palucka to evaluate current approaches to the
validation of known immune response biomarkers and
the standardization of the respective assays to enhance the
likelihood of obtaining informative returns from ongoing
immunotherapy protocols at different institutions. This
working group will focus primarily on the standardization
and corroboration of commonly utilized assays for meas-
urement of host-tumor interaction and immune response
to therapeutic intervention; in addition, it will develop
best practices for the standardization and corroboration
of novel assays.
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Goals
This working group goal consists of testing novel, cutting-
edge strategies suitable for high-throughput screening of
clinical samples for the identification, selection and vali-
dation of biomarkers relevant to disease outcome and/or
to serve as surrogate equivalents to clinical outcome. In
particular, the working group will focus on:
A. Predictors of immune responsiveness are defined as a
set of biomarkers that could predict at the time of patient's
enrollment her/his responsiveness to treatment [2,3]. This
type of markers will be particularly important in immuno-
therapies since standard response criteria (RECIST and
WHO) to define tumor response and disease progression
(tumor shrinkage) might not adequately capture the clin-
ical benefit. In immunotherapy trials, some patients dem-
onstrate long-term survival benefit from treatment but
delayed responses and show continued tumor growth ini-
tially [4]. By standard criteria, such patients would be clas-
sified as having progressive disease and taken off study.
B. Markers predicting risk of toxicity are defined as
biomarkers that could predict at the time of patient's
enrollment her/his likelihood to suffer major toxicity
from a specific therapy.
C. Mechanistic biomarkers are defined as those that may
explain or validate the mechanism(s) of action of a given
treatment in humans; such biomarkers will be more likely
identified by paired comparison of pre- and post-treat-
ment samples[5]. Critical to the design of studies aimed at
the identification of mechanistic biomarkers will be the
inclusion of relevant control samples to allow the differ-
entiation between treatment related effects from the
effects on tissues of serial biopsies that induce wound
repair associated genes and proteins [6].
D. Prognostic markers predicting survival/clinical benefit
could predict overall outcome independent of clinical
responsiveness based on standard response criteria [7,8].
E. Surrogate (end-point) biomarkers are defined as those
biomarkers that could provide information about the
likelihood of clinical benefit/survival at earlier stages
compared to prolonged disease-free or overall survival
analysis.
The goals of this working group are especially challenging
since there are multiple categories of immunotherapies
having their own complexities often representing multi-
component systems such as vaccines. Nevertheless, there
is a need for biomarkers to determine the effect of the drug
on the tumor as well as assessment of the host immune
response. Thus, the goals are broader and less restrictive
than those of the working group on Biomarker Validation and
Application because specific challenges to the identifica-
tion and validation of biomarkers using novel and rapidly
evolving approaches have been less clearly characterized.
Consequently, the establishment of sub-committees
addressing specific issues is planned at a later time either
before or after the 2009 workshop when defined scientific
or practical hurdles will be prioritized and framed into
specific questions. Furthermore, the selection and imple-
mentation of different sub-committees will follow an
adhocracy model according to evolving and progressively
recognized needs [9].
Basic considerations
Success will only be achieved by boldly following new
strategies likely to provide informative data independent
of other practical or financial considerations. In other
words, a study should be primarily designed following
rigorous and stringent criteria that allow the achievement
of its scientific goals. As the design proceeds to the imple-
mentation phase, other considerations should obviously
be taken into consideration and negotiated carefully, opti-
mizing the balance between them and the likelihood to
obtain the originally desired outcomes. A good example is
the implementation of serial sampling for mechanistic
studies [10]; such strategies have been discussed for a long
time but rarely applied due to a hesitant attitude on the
side of clinicians. On the other hand, examples of the
applicability of such strategies in institutionally approved
protocols is emerging because of the enormous scientific
return that can be obtained from these kinds of studies
[5,11,12]. Therefore, the basic belief in relation to the pur-
poses of this working group is that a clinical study should
be entertained only if likely to provide significant
enhancement of the science of immunotherapy; in other
words, a poorly designed clinical study is worse than no
study at all. Furthermore, identification of novel and rele-
vant biomarkers should be sought by prospectively
designing clinical studies with that purpose rather than
piggybacking ongoing studies.
Marker discovery/development for immunotherapy is
especially challenging since humans are:
i. Polymorphic
ii. Tumors are heterogeneous
iii. Environmental conditions variably affect tumor
development/progressionPage 3 of 10
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studies should confront the challenges of clinical investi-
gation by accruing materials that could comprise the
genetic background of patients, the heterogeneity of their
cancers and other indeterminate factors that may contrib-
ute to patients' and cancer cell phenotypes. This goal can
likely be achieved through a non-linear mathematical
approach based on pattern recognition [13-15]. The lead-
ing hypothesis is that, within a heterogeneous system,
commonalities observed during the occurrence of a partic-
ular phenomenology (i.e. response to therapy) are most
likely to be relevant and/or causative [16]. Thus, the gen-
eral strategy will be to obtain:
i. Samples to address the genetic background of the
patients (germ line DNA, i.e. peripheral blood mononu-
clear cells, PBMCs)
ii. Samples to address the altering phenotypes of immune
cells in relation to the natural history of disease and/or
treatment (i.e. pre, during, and post-treatment PBMCs,
sera or plasma at the same time points, pre-treatment and/
or serial biopsies) that could provide insights about the
identification of biomarkers predictive of responsiveness
or toxicity.
iii. Samples that may provide mechanistic insights about
the relationship between tumor biology and treatment
(i.e. tumor biopsies, sentinel node biopsy etc).
Appropriate sample collection should be considered the
independent variable while the technologies applied for
their analysis may rapidly evolve and will have to adjust;
experts in various fields of genomics, functional genom-
ics, and proteomics will provide useful insights. In addi-
tion, recent interest has risen toward the characterization
of cellular products, tissue or genetically engineered prod-
ucts for adoptive transfer by high throughput technologies
including transcriptional profiling at the messenger RNA
[17] and microRNA [18] level.
It should be emphasized that there is no priority scale
about which of the three lines of investigation is most
important; indeed, only the combination of them can
provide a global view of the pathological process. Further-
more, questions regarding the type of material to be uti-
lized (i.e., DNA, RNA or proteins) underline some naiveté
in the way clinical investigations may be approached. In
an oversimplified view, humans, as multi-cellular organ-
isms, are structured according to a hierarchy of genetic
interactions that go from genomic DNA, to transcription
into RNA and translation into functional units (proteins
in different functional statuses) that may or may not differ
among cells within a tissue or from different tissues. The
study of each layer within this hierarchy provides distinct
information: DNA analysis provides information about
relatively stable characteristic of cells and tissues that may
explain variations among individual patients, or aber-
rances between normal and abnormal tissues; messenger
RNA informs mostly about the reaction of cells to envi-
ronmental conditions; we compare transcriptional analy-
sis to the electroencephalographic responses to
stimulation which inform about the reaction to stimulus;
thus, while mRNA provides information about the "brain
response" of a cell (spikes in response to light), protein
analysis (including functional assays descriptive of pro-
tein activation [19] and/or expression by immune cell
subsets [20]) provides information about what a cell is
doing as the hand covers the eyes when the light is too
strong. Since each component provides different types of
information and one kind cannot be assumed from the
other, clinical research should study humans by evaluat-
ing all components simultaneously at moments relevant
to the natural history of a disease or its response to ther-
apy. Of importance is the realization that protein analysis
confronts particular challenges when studying immuno-
logically relevant soluble factors that are generally present
in low concentrations (though biologically significant) in
body fluids like serum or plasma [21] and potentially exist
as isoforms with different functional implications [22].
Advances in metabolic imaging based on positron emit-
ting tomography (PET) and in sensitive protein assays
based on nanotechnology platforms provide the promise
of non-invasive and minimally-invasive immune moni-
toring. The use of PET-based probes preferentially taken
up by activated T cells enables non-invasive imaging of
immune responses in vivo without perturbing the biologi-
cal process with blood cell or tissue sampling [23,24]. In
addition, the increased knowledge of the proteins secreted
during immune activation and tumor cell killing (secre-
tome) can be detected in small volume serum samples
(ideally from a finger-prick) when analyzed by high
throughput nanotechnology-based assays [25,26]. These
new technologies applied to immune monitoring would
enable the sequential and repetitive analysis of an effec-
tive immune response. Ideally, the novel assay technolo-
gies will need to first be compared to more standard
approaches to define their analytical bias, leading to ade-
quate correlation with biological processes and clinical
outcomes. Furthermore, circulating RNA profiling meas-
ures predominantly transcriptional activation of circulat-
ing cells, while protein profiling measures abundance of
proteins produced by several tissues.
General strategy
Experience from non-linear, pattern-recognizing
approaches such as whole genome analysis or functional
genomics suggest that the best and most efficient statisti-
cal strategy for biomarker identification/validation is a
two (three) step process that includes:Page 4 of 10
(page number not for citation purposes)
Journal of Translational Medicine 2008, 6:81 http://www.translational-medicine.com/content/6/1/81i. A discovery/training step
This step may require a relatively limited number of sam-
ples to be tested extensively to identify putative informa-
tive pathways or genetic traits using costly, high-
throughput and comprehensive strategies.
ii. A training/validation step
This bears the same characteristics of the training set with
two exceptions: a) should be performed by an independ-
ent group; b) could be better powered because the study
can be designed with a priori knowledge of experimental
variance.
iii. A validation step
The validation set follows to validate the previously iden-
tified pathway or genetic trait using less costly and more
focused analyses on larger patient populations. Thus, the
validation step bears the same characteristics of the train-
ing/discovery set but it should be performed in a large
independent specimen cohort sufficient to provide the
results to support the clinical use of the marker (prognos-
tic response, toxicity, etc.). It should include a clear statis-
tical design to assure the marker correlation with the
clinical parameter of interest
Key to successful implementation of this strategy is the
decision to move from the "discovery phase" (training
set) to the "validation phase". Arguably, in the past the
scientific community has been too eager to move from the
first to the second without substantial evidence that the
first phase had been truly completed. It could be argued
that a second "training/validation" set should be added to
independently test the reproducibility of the results in a
small cohort; several strategies may be adopted including
a paired performance of identical studies at two different
institutions blinded about each others results. Bioinfor-
matic and statistical support are critical in defining the
most effective and least time-consuming strategies and we
advocate that a biostatistician/computational biologist
should play a significant role in the committee. Moreover,
the separation between training and validation phases is
critical because sample collection, storage and utilization
may significantly vary; less material may be required dur-
ing the validation step when narrower questions are
approached. However, while some features of sample col-
lection may change, experimental consistency will not be
negotiable. The three step strategy may be able to provide
the highest yield of information during the transition
from a high cost per patient during the exploratory phase
to a less costly per patient but highly powered validation
phase. Bioinformatics and statistical support are critical in
defining the most effective and least time-consuming
strategies and we advocate that a biostatistician, computa-
tional biologist should play a significant role in the work-
ing group starting from the clinical study design.
Strategy for sample collection
A working hypothesis of the working group is that the big-
gest obstacle to the identification of useful biomarkers is
the difficulty in obtaining relevant material to study,
while the potential of current technologies is proportion-
ally limitless. Due to practical, ethical and financial
rationalizations, samples are rarely collected with a meth-
odology that allows broad testing opportunities and at a
time or anatomical site relevant to the question asked. The
working group will address each of these questions by
including a bioethicist, members of regulatory agencies
and a statistician together with the clinical and research
input provided by other members and, potentially,
patients' advocacy groups. The contention is that 1) exces-
sive and unnecessary regulatory burdens ultimately result
in a disservice to present and future patients, 2) studies
limited for financial reasons are likely to be more wasteful
than well-designed costly studies because they will even-
tually need to be repeated; 3) the application of training/
validation strategies may significantly reduce costs with-
out compromising the scientific yield of well-designed
studies. Strategies for sample collection include the fol-
lowing:
i. Time of collection
The time of collection critically impacts functional stud-
ies. Obviously, it is less important when analyzing the
genetic background of individuals since germ line DNA
does not change throughout the natural history of the dis-
ease. However, functional studies involving the utiliza-
tion of messenger RNA or protein from samples before
and during treatment are highly affected by the rapid
kinetics of the immune response and the evolving nature
of cancer cell phenotypes.
ii. Method of collection
Clinical samples are often difficult to obtain, impractical
and require invasive technology. Although these are
important considerations, none should compromise the
collection of informative material. Non-invasive technol-
ogies have been developed, validated and optimized dur-
ing the last decade to improve the feasibility of high-
throughput studies in clinical settings [10]. Furthermore,
use of anti-coagulants and/or other preservatives may
have significant impact on measurements [27].
iii. Method of preservation
Strategies can be implemented to preserve materials pro-
spectively in selected cohorts of patients (training set strat-
egy) to improve the quality of the specimens; rapid
freezing methods, use of anti-proteases or anti-RNAase,
aliquoting of material to avoid serial freeze-and-thaw
cycles. These precautions will increase significantly the
likelihood of obtaining informative results by reducing
variance.Page 5 of 10
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DNA, RNA and protein material should be obtained
whenever possible. Germ-line DNA is important for test-
ing genetic predisposition/influence on treatment out-
come. However, genetic testing often requires a large
number of cases due to the functional redundancy of
human genes and the co-segregation of genetic traits
according to geo-ethnical origin independent of specific
phenomenologies. Expertise from immunogeneticists will
be important. Transcriptional analysis has matured dur-
ing the last decade and expertise in RNA handling and
amplification will be present in the working group. A pro-
tein biochemist will be included that could provide exper-
tise about the sample handling and research approaches
appropriate for immunological studies (i.e. low concen-
tration of cytokines and chemokines below the sensitivity
of present discovery-driven proteomic approaches).
v. Number of samples
Individual protocols will require a different number of
samples to achieve the same statistical power according to
the variance expected in the study population and its
responsiveness to therapy and/or susceptibility to toxic
side effects (i.e. the expected frequency of responders to a
given treatment will dictate the size of training and predic-
tion set). Moreover, definition in mathematical terms of
biological equivalence vs diversity of cellular and biologi-
cal products will be discussed (i.e. what parameter defines
equality or difference of dendritic cell processing follow-
ing "identical" procedures).
vi. Methods of analysis
Concerns often focus on methods for sample collection
and storage and validation and cross-validation on novel
technologies. We believe that the significance of these
concerns is overrated, particularly in the case of hypothe-
sis-generating studies where the main goal is to screen
clinical material for the identification of novel ideas to be
validated later on by other techniques. This opinion is
based on evidence that results obtained by various groups
collimate conceptually with results obtained by others
using different platforms and samples and with common
sense biological knowledge [28-32]. As human biology is
an independent variable, different platforms applied to its
study should provide concordant results as the essence of
life is not changed by the spectacles through which we
observe it, though our perceptions might vary from jolly
to gloomy in accordance with the pink or dark lenses that
we wear. This is critical in clinical research: by far, the key
concern should be timing, site and method of sample
accrual while rapidly evolving technologies will have to
adapt to what is available and worth studying. Although
counterintuitive, the methods applied for the study are
less critical than the quality of the material accrued. Expe-
rience with various functional genomics platforms suggest
that results are quite comparable as long as the same
material is tested but most discrepancies occur when stud-
ies performed at different institutions or on samples
received from different institutions are compared. The
potentials of modern technology are proportionately lim-
itless and flexible; bioinformatics tools can robustly eval-
uate concordance of results, identify consistent and
random biases and sieve reliable data. As technology rap-
idly evolves, tools can be adapted to compare platforms
and provide biologically consistent results. Thus,
although the quality of the material will remain a primary
focus of the working group, the need for platform stand-
ardization or, at least comparability of results to facilitate
inter-trial, inter-institutional comparisons will be a focus
of discussion. Furthermore, the definition used for the
collection of clinical information or metadata derived
from the bedside vary widely and are likely to make the
task of consolidating clinical trials results even more
daunting.
vii. Standardization, Centralization, Validation
Although the principles of standardization and validation
of assays are the primary purpose of the working group on
"Biomarker Validation and Application", sound strategies
should be applied to address the imminent needs of the
present working group evaluating novel technologies in
uncharted territories; it is our opinion that assay standard-
ization is most important in the early phases of biomarker
discovery when limited sample size of different protocols
can be counterbalanced by the accumulation of compara-
ble results from different studies/institutions. Thus, the
following concepts will be considered:
i. Standardization
It is generally difficult to enforce standardization of meth-
ods when novel technologies are approached due to the
unsolved biases among individual investigators about the
pros and cons of emerging technologies. Thus, standardi-
zation could be enforced by proposing standardization of
sample collection (comparable material) and cross valida-
tion of the samples among different institutions to assure
similar results independent of platform used.
ii. Sample exchange
The comparability of results could be compared by
exchange of training samples among trials/institutions.
This may obviate biased selection of platforms based on
limited knowledge about their pros and cons.
iii. Centralization
A super core facility could support the analysis of samples
from different but comparable trials as, for instance, the
novel Center for Human Immunology which is part of an
inter-NIH initiative with pre-dominant intra-mural
scopes but open to extra-mural interactions.Page 6 of 10
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it is important to distinguish between these two concepts:
1) assay validation; 2) biomarker validation
1. Assay validation: is not the purpose of this working
group; validation of assay deemed useful by this working
group will be performed by the sister working group after
discussion of its potential benefits.
2. Biomarker validation: potential discovery of a new
robust candidate as a biomarker will need to be validated
by a validation set as described above: this is part of the
goals of the working group; arguably, a robust biomarker
should be useful independent of the test applied. In gen-
eral, concordant results about the validity of a biomarker
by different platforms should provide stronger confidence
about its clinical relevance. Hence, this working group
will not focus particular attention on assay validation but
rather on biomarker validation.
Data exchange
Data collection and data exchange is becoming extremely
burdensome: a whole genome SNP array from Affymetrix
requires approximately 1 Gbyte of memory. Data
exchange requires compatible databases and similar lan-
guages which are not readily available. Thus, informatics
distances are large in spite of the disruption of geographi-
cal distances through the World Wide Web. Centralization
of information may represent a solution as exemplified by
the Center of Information Technology at NCI that stand-
ardizes and collects all high-density data for the intra-
mural program. Similarly, data analysis could be central-
ized as several inter-institutional cooperative groups are
already doing for low density data handling. Large bioin-
formatics wastelands could be avoided if data could be
effectively mined by various groups interested in similar
problems; however, in our experience this seldom occurs
due to the complexity of exchanging basic information
about the strategies in which data bases were prepared
particularly considering the little incentive due to little
funding available for re-analysis and unclear publication
opportunities.
Working group on biomarker validation and application
Co-Chairs: Lisa H. Butterfield, PhD – University of Pitts-
burgh
Nora Disis, MD – University of Washington
A. Karolina Palucka, MD, PhD – Baylor Institute for
Immunology Research
Desired outcomes
This working group has clearly defined goals that can be
summarized as follows:
1) Identification of recommended SOPs for blood, serum/
plasma and PBMC transportation, processing, cryopreser-
vation and thawing. Many of these have been previously
tested, standardized and published [33-35]. Specific pro-
tocols and SOPs should be posted on the web and broadly
available for use and citation. In addition, sample collec-
tion and storage should take into account new assays.
Similar considerations should be taken into account when
collecting sera or plasma during the conduct of clinical tri-
als [36].
2) The identification of specific standardized and vali-
dated immunological assays for both potency of products
and testing of immunologic biomarkers which incorpo-
rate intra-assay and inter-assay reference standards for
comparison between laboratories and potentially
between clinical trials, as well as standardization of assay
data reporting. Again, there have been many reports pub-
lished in these areas [37], and this group proposes to
review the state of the art, including recent undertakings
of related international societies, and present a consensus.
Our goals are to identify a few assays which are minimally
required in a trial to identify successfully vaccinated
patients and patients who would respond to specific
immunotherapy (and to allow for potential inter-trial
comparisons). Also, the activity of this group will focus on
criteria for assessment of analytical range and sensitivity,
accuracy, precision and reproducibility for assay valida-
tion. The group will also identify the most commonly
used assay controls and reagents which might be recom-
mended and made available for common use. Recom-
mended cellular product potency assays should be tested
now, in Phase I/II trials, in preparation for use in any
Phase III trials.
Lastly, 3) the integration of standardized and/or validated
assays (with recommended data reporting parameters)
into new clinical trial design and outcome structure will
be recommended.
Critical Issue for discussion
How to take best advantage of the work in the infectious
disease and immune tolerance fields where much stand-
ardization has already been worked through and imple-
mented?
Charges
1. Identification of validated SOPs for blood handling
and transportation, processing, cryopreservation and
thawing, with new assays in mind.
2. Development of guidelines for pre-analytical standard-
ization, requirements for assay validation and results
reporting that meet CLIA requirements.Page 7 of 10
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significant definitions of immune response based on
immune monitoring assays. This would require defining
the performance specifications within the reportable
range of the assay, as described [38]. Assays should specify
whether they are quantitative or semi-quantitative, the
scoring system and threshold values that differentiate
between responders and non responders must be speci-
fied.
4. Source for standard cell lines (T2, K562/A2.1, etc.) and
culture SOPs.
5. Identification of potency assays for cellular products for
development and testing in current immunotherapy tri-
als: a) cellular vaccine phenotypes (DC, other APC, CTL/
TIL, NK, NK/T), b) cytokine/chemokine production, c)
antigen uptake/presentation and d) functional assessment
[39].
6. Develop specific guidelines for detection of T cell fre-
quencies: IFN-γ ELISPOT [40] and for "other cytokine"
ELISPOTs, intracellular cytokine staining, cytotoxicity
assays, proliferation, (focus on non radioactive and multi-
parameter), specific antigen ELISA/Luminex and MHC
class I tetramer flow cytometry. For most routine assays, a
simple statement of general parameters with citations.
7. Develop strategies for standardization and validation of
monitoring non-HLA-A2.1 patients, particularly the use
of long peptides, peptide libraries and full-length anti-
gens.
8. Identification of a few core assays which are minimally
required in a trial to identify successfully vaccinated
patients and/or patients who respond to a specific immu-
notherapy. Particularly, the least costly assay which is
standardized and/or validated, with freely available refer-
ence standards which can be used in each assay run. This
should include specific recommendations for assay
parameters, coefficient of variation (CV) and data analysis
to report in publications. This should also include defin-
ing the analytical variation of the assay as well as deter-
mining the biological fluctuations of antigen-specific T
cells in humans over time in the absence of an interven-
tion [41].
9. Development of assay reference standards that meet
CLIA requirements. Recommend optimal sources of criti-
cal reagents.
10. Identification of scientific areas in which assays
should be developed, including apoptosis, myeloid-
derived suppressor cells, tumor microenvironment assess-
ment, discussion of issues inherent to antigen-specific
DTH testing, and T regulatory cells assessment. This
should be based on a systematic approach of method
selection, evaluation, development and implementation
(specific recommendations available on the web, [42].
There are increasingly frequent reports of statistically sig-
nificant correlations between measures of anti-tumor
immunity and clinical outcome. Greater standardization
is required to strengthen these associations and provide
more mechanistic insights to inform future trial design. In
addition, utilization of CLIA-certified and inspected cen-
tral laboratories allows for standardization of most
aspects of assay conduct and also for cost effective assay
development and validation.
Expected milestones for both working groups
• The 2009 iSBTc Workshop preceding the 2009 Annual
Meeting [1].
• Preparation of a document with input from all partici-
pants at the end of the task force to be published after the
2009 Workshop (as done in previous occasions [43,44]).
• Provision of links to recommended SOPs and the result-
ant document on the iSBTc web site with links to the web
sites of participating societies and organizations.
Expected outcomes of the taskforce
• Potential collaborations among different laboratories,
institutions, companies and international societies which
are also focused on similar efforts of standardization and
harmonization of goals.
• Development of cooperative groups for the study
design, identification and sharing of resources, centraliza-
tion of analyses in core laboratories, establishment of ad
hoc tissue and data banks and development of easy to
access data repositories.
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